Palbociclib, a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor, prolongs progression-free survival among patients with advanced estrogen receptor-positive and HER2-negative breast cancer [18, 19]. This evidence concerns the gene ESR1 and breast cancer.